Published in Neurology on January 25, 2005
Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol (2013) 2.08
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. J Neurol (2007) 1.08
The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol (2008) 1.05
Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2009) 0.90
Optimizing treatment success in multiple sclerosis. J Neurol (2015) 0.90
Predictive value of early brain atrophy on response in patients treated with interferon β. Neurol Neuroimmunol Neuroinflamm (2015) 0.89
Neuroprotective effects of testosterone treatment in men with multiple sclerosis. Neuroimage Clin (2014) 0.88
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord (2013) 0.87
Neuroimaging in multiple sclerosis: neurotherapeutic implications. Neurotherapeutics (2011) 0.85
MRI correlates of disability progression in patients with CIS over 48 months. Neuroimage Clin (2014) 0.83
Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. J Neurol (2015) 0.81
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults? Mult Scler Int (2011) 0.77
Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome. PLoS One (2016) 0.75
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. BMC Med Imaging (2016) 0.75
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med (1985) 8.45
Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med (1989) 6.37
Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med (1993) 5.39
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Acupuncture in patients with osteoarthritis of the knee: a randomised trial. Lancet (2005) 4.08
The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler (1999) 3.71
Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. Ann Intern Med (1982) 3.56
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol (2002) 3.17
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol (1995) 3.06
Locoregional cancer treatment with magnetic drug targeting. Cancer Res (2000) 3.05
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology (2005) 2.95
Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 2.62
Health of the public: The private-sector challenge. JAMA (1996) 2.50
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology (1999) 2.40
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33
Type C botulism in dairy cattle from feed contaminated with a dead cat. J Vet Diagn Invest (2000) 2.32
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
The distance to community medical care and the likelihood of hospitalization: is closer always better? Am J Public Health (1997) 2.21
Efficacy of dexmedetomidine compared with midazolam for sedation in adult intensive care patients: a systematic review. Br J Anaesth (2013) 2.17
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology (2002) 2.12
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07
Human haploinsufficiency--one for sorrow, two for joy. Nat Genet (1994) 2.06
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology (2010) 2.04
Variation in the HHEX-IDE gene region predisposes to type 2 diabetes in the prospective, population-based EPIC-Potsdam cohort. Diabetologia (2007) 2.02
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol (1998) 1.97
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A (1990) 1.93
Self glycolipids as T-cell autoantigens. Eur J Immunol (1999) 1.93
Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. Circulation (1996) 1.91
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Geographic variation in hospice use prior to death. J Am Geriatr Soc (2000) 1.90
Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry (2009) 1.89
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
Peduncular 'rubral' tremor and dopaminergic denervation: a PET study. Neurology (1995) 1.84
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology (2011) 1.83
The compromised host and Legionnaires' disease. Ann Intern Med (1979) 1.83
Eight-year follow-up study of brain atrophy in patients with MS. Neurology (2002) 1.78
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology (2010) 1.75
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology (2011) 1.75
Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem (1999) 1.73
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity (2000) 1.72
Key importance of the Helicobacter pylori adherence factor blood group antigen binding adhesin during chronic gastric inflammation. Cancer Res (2001) 1.67
Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol (1997) 1.66
Neuroimaging predictors of transition to psychosis--a systematic review and meta-analysis. Neurosci Biobehav Rev (2010) 1.65
The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler (2009) 1.65
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler (2009) 1.65
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology (2002) 1.61
Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology (1990) 1.61
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev (2001) 1.59
Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry (2003) 1.58
Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 1.57
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology (2002) 1.56
Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology (1997) 1.55
Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology (2003) 1.54
Multiple sclerosis. The spectrum of severity. Arch Neurol (1983) 1.54
Racial differences in fracture risk. Epidemiology (1994) 1.54
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology (2001) 1.53
Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging (2002) 1.50
Sporadic--but not variant--Creutzfeldt-Jakob disease is associated with polymorphisms upstream of PRNP exon 1. Am J Hum Genet (2001) 1.50
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Absence of linkage to 8q24 in a European family with familial adult myoclonic epilepsy (FAME). Neurology (2002) 1.48
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
Biomechanical effect of isolated capitate shortening in Kienbock's disease: an anatomical study. J Hand Surg Eur Vol (2012) 1.45
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry (1997) 1.44
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology (2001) 1.44
Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology (2005) 1.43
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun (2008) 1.43
Late morbidity following nerve-sparing radical hysterectomy. Gynecol Oncol (2009) 1.41
Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. J Virol Methods (1998) 1.41
Decision-making and outcomes of prolonged ICU stays in seriously ill patients. J Am Geriatr Soc (2000) 1.41
Towards a european network for multiple sclerosis trials (ENMST). Mult Scler (2003) 1.40
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol (2000) 1.39
High prevalence of FDB3500 mutation in the Swiss population. Atherosclerosis (2000) 1.39
Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy (2007) 1.39
Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology (2004) 1.39
Effect of dose on the absorption and excretion of [14C]benzene administered orally or by inhalation in rats and mice. Toxicol Appl Pharmacol (1987) 1.34
Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology (2005) 1.33
Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs (1995) 1.33